Rapid Clearance Provides Clinical Advantages

MYOVIEW clears quickly from the blood, liver, and lungs, creating:

  • High target-to-background ratios 1-4
  • Timely imaging-as soon as 15 minutes, up to 4 hours postinjection 3
  • Flexibility in camera scheduling 4-5
  • Increased patient throughput 4-5
  • Opportunity for timely patient management 3-5

Rapid Clearance Enhances Image Quality

Rapid clearance from extra-cardiac organs:

  • Reduces artifacts from surrounding organs 2,5
  • Improves image integrity 3,5
  • Optimizes heart visualization 3,5
  • Aids physician in diagnostic confidence 3-5

Myocardial Perfusion Imaging (MPI) Is Growing and So Is the Use of MYOVIEW

MPI studies show steady increases year by year 6,7

  • More than 2.9 million MYOVIEW doses sold in the u.s. in 20016,7
  • MYOVIEW share of the Tc99m cardiac market has grown to 36%+ in 5 years 6,7
  • 70% of the Tc99m-based MPI market is under national contract with MYOVIEW 7
  • MYOVIEW continues to grow in other countries: market share in Europe-56%; market share in Japan-70 % 7

In studying patients with known or suspected coronary artery disease, care should be taken to ensure continuous cardiac monitoring and the availability of emergency cardiac treatment. As with all injectable drug products, allergic reactions, and anaphylaxis may occur.
 
Pharmacologic induction of cardiovascular stress may be associated with serious adverse events, such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, and cerebrovascular events. Caution should be used when pharmacologic stress is selected as an alternative to exercise; it should be used when indicated and in accordance with the pharmacologic stress agent's labeling. The most common adverse reactions reported from post-marketing experience included rash, urticaria, abnormal vision, allergic reactions, and fever.

References: 1. MYOV1EW prescribing informatian. 2. Iskandrian AE, Verani MS. Nuclear imaging techniques. In: Topal EJ, ed. Textbook of Cardiovascular Medicine. Philadelphia, Pa.: Lippincott-Raven; 1998: 1367-1371. 3. Higley B, Smith FW, Smith T, et al. Technetium-99m-1 ,2-bis[bis(2-ethoxyethyl)phosphino]ethane: human biodistribution, dosimetry and safety of a new myocardial perfusion imaging agent. J Nucl Med. 1993;34:30-38. 4. Munch G, Neverve J, Matsunari I, Schroter G, Schwaiger M. Myocardial technetium-99m-tetrofosmin and technetium-99m-sestomibi kinetics in normal subjects and patients with coronary artery disease. J Nucl Med. 1997;38:428-432. 5. Jain D. Technetium-99m labeled myocardial perfusion imaging agents. Semin Nucl Med. 1999;29:221-236. 6. Data on file, Arlington Medical Resources Inc., Malvern, Pa. 7. Data on file, Amersham Health.